Diabetes Breakthrough: New Treatment Eliminates Insulin for 86% of Patients
17th October 2024
A new treatment combining ReCET and semaglutide could eliminate the need for insulin in type 2 diabetes, with 86% of participants in a study no longer requiring insulin therapy. The treatment was safe and well-tolerated, and further trials are planned to confirm these results.
Groundbreaking research presented at UEG Week 2024 introduces a promising new treatment approach for type 2 diabetes (T2D) that has the potential to greatly reduce or even eliminate the need for insulin therapy.
This innovative approach, which combines a novel procedure known as ReCET (Re-Cellularization via Electroporation Therapy) with semaglutide, resulted in the elimination of insulin therapy for 86% of patients.